Cargando…

PTEN Regulates PI(3,4)P(2) Signaling Downstream of Class I PI3K

The PI3K signaling pathway regulates cell growth and movement and is heavily mutated in cancer. Class I PI3Ks synthesize the lipid messenger PI(3,4,5)P(3). PI(3,4,5)P(3) can be dephosphorylated by 3- or 5-phosphatases, the latter producing PI(3,4)P(2). The PTEN tumor suppressor is thought to functio...

Descripción completa

Detalles Bibliográficos
Autores principales: Malek, Mouhannad, Kielkowska, Anna, Chessa, Tamara, Anderson, Karen E., Barneda, David, Pir, Pınar, Nakanishi, Hiroki, Eguchi, Satoshi, Koizumi, Atsushi, Sasaki, Junko, Juvin, Véronique, Kiselev, Vladimir Y., Niewczas, Izabella, Gray, Alexander, Valayer, Alexandre, Spensberger, Dominik, Imbert, Marine, Felisbino, Sergio, Habuchi, Tomonori, Beinke, Soren, Cosulich, Sabina, Le Novère, Nicolas, Sasaki, Takehiko, Clark, Jonathan, Hawkins, Phillip T., Stephens, Len R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678281/
https://www.ncbi.nlm.nih.gov/pubmed/29056325
http://dx.doi.org/10.1016/j.molcel.2017.09.024
Descripción
Sumario:The PI3K signaling pathway regulates cell growth and movement and is heavily mutated in cancer. Class I PI3Ks synthesize the lipid messenger PI(3,4,5)P(3). PI(3,4,5)P(3) can be dephosphorylated by 3- or 5-phosphatases, the latter producing PI(3,4)P(2). The PTEN tumor suppressor is thought to function primarily as a PI(3,4,5)P(3) 3-phosphatase, limiting activation of this pathway. Here we show that PTEN also functions as a PI(3,4)P(2) 3-phosphatase, both in vitro and in vivo. PTEN is a major PI(3,4)P(2) phosphatase in Mcf10a cytosol, and loss of PTEN and INPP4B, a known PI(3,4)P(2) 4-phosphatase, leads to synergistic accumulation of PI(3,4)P(2), which correlated with increased invadopodia in epidermal growth factor (EGF)-stimulated cells. PTEN deletion increased PI(3,4)P(2) levels in a mouse model of prostate cancer, and it inversely correlated with PI(3,4)P(2) levels across several EGF-stimulated prostate and breast cancer lines. These results point to a role for PI(3,4)P(2) in the phenotype caused by loss-of-function mutations or deletions in PTEN.